Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ATAI

Atai Beckley

ATAI Acquired Lead: Phase 2 11 Biotech Distilled articles ↓ 38 filings & releases ↓ Cash $169M (Jun 30, 2026) ↓ 10 verdicts ↓ 2 timing quotes ↓
Neurology Small Molecule

Market cap $2.73B 370.9M shares (10-Q, Aug 7, 2026) × $7.35 close Sep 10, 2026

Most recent annual filing: 2026-03-06

Pipeline (5 active programs)

Capital (as filed)

Cash
$169M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$35.3M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$210M cash, runway early 2029 per the update of May 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on Atai Beckley, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2025-12-24 Speculative buy speculative Atai Beckley (ATAI): Scientific Due Diligence for Lead and Pipeline Products BPL-003 has cleared a real Phase 2b hurdle with plausible biology and Breakthrough Therapy designation, offering asymmetric upside for investors who can underwrite binary clinical risk with appropriately sized positions.
  2. 2026-01-11 Hold UPDATE Atai Beckley (ATAI): JPM Update, Phase 3 Timelines, and Cash Runway to 2029 Cash runway confirmed to 2029 removes the primary bear argument; existing holders should stay put while prospective entrants can consider the Q1 EMP-01 binary as an entry point.
  3. 2026-02-28 Buy speculative UPDATE: Atai Beckley (ATAI) - EMP-01 Delivers a Phase 2a Win, But the Market Yawns EMP-01 Phase 2a win strengthens the pipeline thesis and the post-data selloff to mid-$3 range offers an attractive entry ahead of the BPL-003 Phase 3 catalyst.
  4. 2026-03-07 Buy speculative UPDATE: Atai Beckley (ATAI) - FDA Greenlights BPL-003 Phase 3; 10-K Confirms 2029 Runway FDA EOP2 alignment on BPL-003 Phase 3 design and 10-K confirmation of 2029 runway have drastically reduced foundational risks, with Phase 3 initiation as the next major catalyst.
  5. 2026-03-22 Buy speculative UPDATE: Atai Beckley (ATAI) - BPL-003 Gets Peer-Reviewed Validation as Phase 3 Approaches Peer-reviewed 12-week durability data and initiation of the commercial-model Cohort 4 trial confirm continued execution ahead of the Q2 Phase 3 initiation.
  6. 2026-03-29 Buy speculative UPDATE: Atai Beckley (ATAI) - The Index Effect Takes Hold Ahead of Q2 S&P Total Market and CRSP index inclusion creates a structural passive-buying floor that stabilizes the stock ahead of the Q2 BPL-003 Phase 3 initiation catalyst.
  7. 2026-04-27 Buy speculative UPDATE: AtaiBeckley (ATAI) - Two Data Drops, One 38% Rally, and the Phase 3 Clock Ticking Peer-reviewed SSRI-adjunctive BPL-003 data and expanded EMP-01 dataset with Hedges' g=0.84 compound the thesis; the stock is re-rating as Phase 3 initiation approaches.
  8. 2026-05-12 Buy speculative UPDATE: AtaiBeckley (ATAI) - The Phase 3 Blueprint, Decoded Phase 3 design is now fully disclosed (580 patients, Week 4 MADRS primary, 52-week OLE) with a 2029 topline date; the thesis is intact but this is a three-year binary carry, not a near-term trade.
  9. 2026-07-06 Buy speculative UPDATE: AtaiBeckley (ATAI) - VLS-01 Graduates from Hedge to Second Pillar VLS-01 is being repositioned as a co-lead asset targeting MDD Phase 3 conditional on Q4 Elumina data, expanding the pipeline's strategic value while BPL-003 Phase 3 enrolls toward a 2029 readout.
  10. 2026-07-16 Exit UPDATE: AtaiBeckley (ATAI) — Lilly Buys the Thesis for $2.8B + CVRs Eli Lilly's $6.75/share cash acquisition plus CVRs realizes the thesis; no more clinical binary risk on the underlying shares, and holders should sell or hold through close for CVR optionality depending on risk appetite.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (38)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)